ECSP066873A - Compuestos hmb y usos parecidos - Google Patents
Compuestos hmb y usos parecidosInfo
- Publication number
- ECSP066873A ECSP066873A EC2006006873A ECSP066873A ECSP066873A EC SP066873 A ECSP066873 A EC SP066873A EC 2006006873 A EC2006006873 A EC 2006006873A EC SP066873 A ECSP066873 A EC SP066873A EC SP066873 A ECSP066873 A EC SP066873A
- Authority
- EC
- Ecuador
- Prior art keywords
- patient
- hmb
- present
- administration
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 abstract 7
- 206010028980 Neoplasm Diseases 0.000 abstract 4
- 238000012512 characterization method Methods 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 229940024606 amino acid Drugs 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000002265 prevention Effects 0.000 abstract 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 102000003945 NF-kappa B Human genes 0.000 abstract 1
- 108010057466 NF-kappa B Proteins 0.000 abstract 1
- 102000003923 Protein Kinase C Human genes 0.000 abstract 1
- 108090000315 Protein Kinase C Proteins 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- 102000044159 Ubiquitin Human genes 0.000 abstract 1
- 108090000848 Ubiquitin Proteins 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229960004203 carnitine Drugs 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Nutrition Science (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
Abstract
La presente invención tiene relación con los procedimientos para la prevención y tratamiento de enfermedades inflamatorias crónicas, cáncer y pérdida involuntaria de peso. En la práctica de la presente invención, a los pacientes se les administra por vía enteral HMB sólo o alternativamente en combinación con eicosapentanóico (20:5 ?-3), FOS, carnitina y mezclas parecidas.En otra caracterización, la presente invención provee un procedimiento para el tratamiento del enflaquecimiento de un paciente asociado con una enfermedad. El procedimiento comprende la administración al paciente de la composición arriba descrita, que contiene HMB en cantidades suficientes para tratar el desgaste asociado con la enfermedad, en el cual, con la administración del compuesto al paciente se trata el desgaste asociado con la enfermedad. En otra caracterización, la presente invención provee un procedimiento para reducir la tasa de crecimiento del tumor en un paciente. El procedimiento consiste en la administración a un paciente el compuesto arriba descrito, que contiene HMB en cantidad suficiente para reducir la tasa de crecimiento del tumor, en el cual, luego de la administración la tasa de crecimiento del tumor es reducida.En otra caracterización, la presente invención provee un procedimiento para la prevención o tratamiento de la enfermedad en pacientes, reduciendo la regulación de la expresión y/o actividad de la proteína kinasa C, el factor nuclear kappa-B, enzimas que conjugan ubiquitina y componentes de proteasoma 26S. Estos procedimientos consisten en la administración a un paciente de HMB, sales, metabolitos o derivados parecidos. Todavía en otra caracterización, el HMB puede ser agregado a productos alimenticios que contienen una fuente de amino-nitrógeno enriquecida con grandes aminoácidos neutros como la leucina, isoleucina, valina, tirosina, treonina y fenilalanina y sustancialmente carente de aminoácidos libres.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/810,762 US20050215640A1 (en) | 2004-03-26 | 2004-03-26 | HMB compositions and uses thereof |
| PCT/US2005/007951 WO2005102301A2 (en) | 2004-03-26 | 2005-03-14 | Hydroxymethylbutyrate compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP066873A true ECSP066873A (es) | 2006-11-24 |
Family
ID=34990887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2006006873A ECSP066873A (es) | 2004-03-26 | 2006-09-22 | Compuestos hmb y usos parecidos |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US20050215640A1 (es) |
| EP (3) | EP1727534A2 (es) |
| JP (3) | JP5145033B2 (es) |
| KR (2) | KR101253063B1 (es) |
| CN (1) | CN101212961A (es) |
| AU (1) | AU2005235133B2 (es) |
| BR (1) | BRPI0509017A (es) |
| CA (2) | CA2807787C (es) |
| EC (1) | ECSP066873A (es) |
| ES (2) | ES2586402T3 (es) |
| IL (1) | IL178039A0 (es) |
| MX (1) | MXPA06010922A (es) |
| TW (1) | TWI369981B (es) |
| WO (1) | WO2005102301A2 (es) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| PL371081A1 (pl) * | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
| NZ568611A (en) | 2005-12-19 | 2011-11-25 | Abbott Lab | Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production |
| US9358242B2 (en) * | 2007-08-30 | 2016-06-07 | Prelief Inc. | Calcium glycerophosphate for treating and preventing respiratory diseases or conditions |
| US9707241B2 (en) | 2008-12-09 | 2017-07-18 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US11173167B2 (en) | 2008-12-09 | 2021-11-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9539224B2 (en) | 2008-12-09 | 2017-01-10 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9259430B2 (en) | 2008-12-09 | 2016-02-16 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| EP2381784B1 (en) * | 2008-12-09 | 2018-07-11 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| US9770424B2 (en) | 2008-12-09 | 2017-09-26 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| SG2014014435A (en) | 2009-02-24 | 2014-07-30 | Ritter Pharmaceuticals Inc | Prebiotic formulations and methods of use |
| SG10201912687WA (en) | 2009-04-29 | 2020-02-27 | Amarin Pharmaceuticals Ie Ltd | Stable Pharmaceutical Composition And Methods Of Using Same |
| CN104042617A (zh) | 2009-04-29 | 2014-09-17 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| EP3698781A1 (en) | 2009-06-15 | 2020-08-26 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid for treating myocardial infarction in a subject on concomitant statin therapy |
| RU2758369C2 (ru) | 2009-09-23 | 2021-10-28 | Амарин Фармасьютикалз Айрлэнд Лимитед | Фармацевтическая композиция, включающая омега-3 жирную кислоту и гидроксипроизводное статина, и способы ее применения |
| CN101704736A (zh) * | 2009-10-30 | 2010-05-12 | 黄再新 | β-羟基-β-甲基丁酸生产过程中氯气逸出时的应急处理方法 |
| US8335592B2 (en) | 2009-11-24 | 2012-12-18 | Pepsico, Inc. | Beverage dispensing device |
| US9754437B2 (en) * | 2009-11-24 | 2017-09-05 | Pepsico, Inc. | Automated beverage formulation |
| US8490829B2 (en) | 2009-11-24 | 2013-07-23 | Pepsico, Inc. | Personalized beverage dispensing device |
| CN102762097B (zh) * | 2009-12-18 | 2015-06-17 | 代谢科技有限公司 | 改进的给药β-羟基-β-甲基丁酸(HMB)的方法 |
| PE20121727A1 (es) * | 2010-01-29 | 2013-01-13 | Abbott Lab | Liquidos nutricionales en envases plasticos que comprenden beta-hidroxi-beta-metilbutirato (hmb) |
| WO2011094557A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Nutritional emulsions comprising calcium hmb |
| US9693577B2 (en) | 2010-01-29 | 2017-07-04 | Abbott Laboratories | Method of preparing a nutritional powder comprising spray dried HMB |
| CA2785522C (en) | 2010-01-29 | 2015-09-29 | Abbott Laboratories | Nutritional emulsions comprising calcium hmb and soluble protein |
| CN106937742A (zh) * | 2010-01-29 | 2017-07-11 | 雅培制药有限公司 | 包含喷雾干燥的hmb的营养粉 |
| EP2461704B1 (en) * | 2010-01-29 | 2013-10-09 | Abbott Laboratories | Aseptically packaged nutritional liquids comprising hmb |
| WO2011137249A1 (en) | 2010-04-28 | 2011-11-03 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| TWI526161B (zh) * | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| EP2444083A1 (en) * | 2010-10-21 | 2012-04-25 | Nestec S.A. | Cysteine and food intake |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| PH12013501292A1 (en) * | 2010-12-22 | 2019-03-22 | Abbott Lab | Nutritional products comprising calcium beta-hydroxy-beta methylbutyrate and conjugated linoleic acid |
| SG191369A1 (en) * | 2010-12-27 | 2013-08-30 | Abbott Lab | Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate |
| EP2672843B1 (en) * | 2011-02-07 | 2018-07-11 | Abbott Laboratories | Nutritional products comprising beta-hydroxy-beta-methylbutyrate |
| US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
| US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
| US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
| US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
| EP2675298A1 (en) | 2011-02-17 | 2013-12-25 | Abbott Laboratories | Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate |
| BR112013025047A2 (pt) * | 2011-03-31 | 2017-02-14 | Nestec Sa | composições nutricionais para aumentar os níveis de arginina e métodos para usar as mesmas |
| US8183227B1 (en) | 2011-07-07 | 2012-05-22 | Chemo S. A. France | Compositions, kits and methods for nutrition supplementation |
| CN103857390A (zh) * | 2011-08-15 | 2014-06-11 | 雅培制药有限公司 | 用于制备hmb及其盐的方法 |
| US8168611B1 (en) | 2011-09-29 | 2012-05-01 | Chemo S.A. France | Compositions, kits and methods for nutrition supplementation |
| WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| US9827219B2 (en) | 2012-01-06 | 2017-11-28 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity C-reactive protein (HS-CRP) in a subject |
| ES2421187B1 (es) * | 2012-02-23 | 2014-11-26 | Abbott Laboratories | Metodo para mejorar el desarrollo cerebral y la funcion cognitiva usando beta-hidroxi-beta-metilbutirato |
| WO2013188258A1 (en) * | 2012-06-11 | 2013-12-19 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
| LT4338805T (lt) | 2012-06-29 | 2025-09-25 | Amarin Pharmaceuticals Ireland Limited | Eikozapentaeno rūgšties etilo esteris, skirtas panaudoti mažinant nemirtino miokardo infarkto riziką subjektui, gydomam statinais |
| US20140037813A1 (en) * | 2012-08-02 | 2014-02-06 | Mead Johnson Nutrition Company | Nutritional creamer composition |
| AU2013312113B2 (en) * | 2012-09-10 | 2018-08-02 | Metabolic Technologies, LLC | Composition of HMB and ATP and methods of use |
| SG11201502069SA (en) * | 2012-09-17 | 2015-05-28 | Abbott Lab | Beta-hydroxy-beta-methylbutryic acid- containing compositions and uses thereof |
| SG11201502205SA (en) | 2012-09-21 | 2015-04-29 | Abbott Lab | Nutritional compositions including calcium beta-hydroxy-beta-methylbutyrate, protein and low levels of electrolytes |
| US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| WO2014113404A1 (en) * | 2013-01-15 | 2014-07-24 | Nusirt Sciences, Inc. | Treating pulmonary conditions |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| CA2901469A1 (en) | 2013-03-08 | 2014-09-12 | Axiom Foods, Inc. | Rice protein supplements |
| US9820504B2 (en) | 2013-03-08 | 2017-11-21 | Axiom Foods, Inc. | Rice protein supplement and methods of use thereof |
| EP2968236A2 (en) | 2013-03-14 | 2016-01-20 | Abbott Laboratories | Treatment of insulin resistance associated with prolonged physical inactivity |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150057350A1 (en) * | 2013-08-23 | 2015-02-26 | Abbott Laboratories | Fibrosis biomarkers and methods of using same |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| JP6349575B2 (ja) * | 2013-12-03 | 2018-07-04 | 小林香料株式会社 | Ｈｍｂを含有する酸性飲料 |
| WO2015094767A1 (en) * | 2013-12-18 | 2015-06-25 | Abbott Laboratories | Methods for maintaining or increasing bodyweight using decaffeinated green tea extract |
| WO2015094925A1 (en) | 2013-12-18 | 2015-06-25 | Capsugel Belgium Nv | Stable liquid filled hard capsule comprising beta-hydroxy-beta-methylbutyric acid |
| WO2015105981A2 (en) * | 2014-01-09 | 2015-07-16 | Abbott Laboratories | Conditional essentiality of hmb |
| HK1223509A1 (zh) * | 2014-03-14 | 2017-08-04 | 代谢科技有限公司 | 含有游离酸形式的β-羟基-β-甲基丁酸盐(HMB)的液体和食品 |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| US20160184248A1 (en) * | 2014-12-15 | 2016-06-30 | University Of Central Florida Research Foundation Inc. | Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response |
| CA2987934A1 (en) * | 2015-06-01 | 2016-12-08 | Metabolic Technologies, Inc. | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for decreasing fat mass |
| US12208073B2 (en) | 2015-09-16 | 2025-01-28 | Metabolic Technologies, LLC | Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma |
| PT3349745T (pt) | 2015-09-16 | 2024-03-18 | Metabolic Tech Inc | Composições e métodos de utilização de beta-hidroxi-beta metilbutirato (hmb) para melhorar a recuperação de traumatismos de tecidos moles |
| AU2017207910B2 (en) * | 2016-01-13 | 2022-09-01 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for joint stability |
| US11406609B2 (en) | 2016-01-21 | 2022-08-09 | Metabolic Technologies, Inc. | Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for modulating autophagy and lipophagy |
| CA3011981C (en) * | 2016-01-21 | 2024-01-16 | Metabolic Technologies, Inc. | Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) for modulating autophagy and lipophagy |
| US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| CA3024584A1 (en) | 2016-05-25 | 2017-11-30 | TSI Group Ltd. | Stabilization of beta-hydroxyisovaleric acid formulations in soft gel capsules |
| JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
| AU2018255269B2 (en) | 2017-04-17 | 2023-03-09 | The University Of Chicago | Polymer materials for delivery of short-chain fatty acids to the intestine for applications in human health and treatment of disease |
| CN110868870A (zh) | 2017-05-12 | 2020-03-06 | 艾斯姆食品公司 | 大米产物及制备它们的系统和方法 |
| TW201900160A (zh) | 2017-05-19 | 2019-01-01 | 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 | 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法 |
| EP3668499A1 (en) | 2017-08-14 | 2020-06-24 | Axcella Health Inc. | Amino acid compositions for the treatment of liver disease |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| CN108558707A (zh) * | 2018-04-13 | 2018-09-21 | 太仓运通新材料科技有限公司 | 一种三肌酸hmb盐的制备方法 |
| EP4534146A3 (en) * | 2018-04-25 | 2025-06-25 | Oncocross Co., Ltd. | Dimenhydrinate and calcium pantothenate for preventing and treating muscular disease |
| WO2019246225A1 (en) | 2018-06-20 | 2019-12-26 | Axcella Health Inc. | Compositions and methods for the treatment of fat infiltration in muscle |
| IL261670B (en) * | 2018-09-06 | 2019-06-30 | Tudu Holdings Ltd | A preparation that includes magnesium and its uses |
| EP3750535B1 (en) | 2018-09-24 | 2025-12-31 | Amarin Pharmaceuticals Ireland Limited | METHODS FOR REDUCING THE RISK OF CARDIOVASCULAR EVENTS IN A SUBJECT |
| US10888576B2 (en) | 2018-10-08 | 2021-01-12 | Metabolic Technologies, Inc. | Composition of HMB and ATP and methods of use |
| JP7286964B2 (ja) * | 2018-12-28 | 2023-06-06 | 日油株式会社 | β－ヒドロキシ－β－メチル酪酸、タンパク質、及び液状油脂を含有する液状栄養組成物 |
| CN111714616A (zh) * | 2019-07-17 | 2020-09-29 | 江苏西宏生物医药有限公司 | 一种用于抗肿瘤的组合物 |
| JP7594356B2 (ja) * | 2019-10-30 | 2024-12-04 | 小林製薬株式会社 | 経口組成物 |
| BR112022009189A2 (pt) | 2019-11-12 | 2022-07-26 | Amarin Pharmaceuticals Ie Ltd | Métodos para reduzir o risco de eventos cardiovasculares em um sujeito com fibrilação atrial e/ou palpitação atrial |
| CN115209886A (zh) * | 2020-03-12 | 2022-10-18 | 雅培制药有限公司 | 治疗腹泻或肠道炎性病状的方法 |
| US20210393559A1 (en) * | 2020-06-17 | 2021-12-23 | Metabolic Technologies, LLC | Compositions and Methods of Use of Beta-Hydroxy-Beta-methylbutyrate (HMB) for Improving Muscle Mass, Strength and Muscular Function Without Exercise |
| US20230398104A1 (en) * | 2020-10-30 | 2023-12-14 | Societe Des Produits Nestle S.A. | Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for rehabilitation |
| EP4236947A1 (en) * | 2020-10-30 | 2023-09-06 | Société des Produits Nestlé S.A. | Compositions containing nicotinamide and vitamin b6 and methods of using such compositions for treating cachexia or precachexia |
| BR112023004232A2 (pt) * | 2020-10-30 | 2023-05-09 | Nestle Sa | Composições contendo nicotinamida e vitamina b6 e métodos de uso de tais composições para tratar sarcopenia e debilidade |
| CN116322686A (zh) * | 2020-10-30 | 2023-06-23 | 雀巢产品有限公司 | 含有烟酰胺和维生素b6的组合物以及使用此类组合物来促进肌肉生长的方法 |
| AU2022263358A1 (en) | 2021-04-21 | 2023-11-30 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| WO2023031226A1 (en) * | 2021-08-31 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of branched chain fatty acids (bcfas) for the treatment of intestinal inflammation |
| DE202023107635U1 (de) * | 2023-12-22 | 2024-02-08 | RenaCare NEPHROMED GmbH | Zusammensetzung zur Eiweißsubstitution |
| CN120837469A (zh) * | 2025-08-06 | 2025-10-28 | 中日友好医院(中日友好临床医学研究所) | β-羟基-β-甲基丁酸作为GSDMD的抑制剂及其抗细胞焦亡的应用 |
Family Cites Families (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US597650A (en) | 1898-01-18 | morris | ||
| US3408210A (en) * | 1965-06-14 | 1968-10-29 | Wilbert A. Heyman | Dehydration of foods |
| US3542560A (en) * | 1967-12-06 | 1970-11-24 | American Home Prod | Infant formula with fat composition like human milk |
| GB1446965A (en) * | 1974-02-14 | 1976-08-18 | Agricultural Vegetable Prod | Preparation of food products |
| US4104290A (en) * | 1975-02-07 | 1978-08-01 | H.L.S. Ltd., Industrial Engineering Company | Process for separating oils and fats into liquid and solid fractions |
| US4311645A (en) | 1980-03-24 | 1982-01-19 | Hoffmann-La Roche Inc. | Synthesis of SRS-active compounds |
| US4871768A (en) | 1984-07-12 | 1989-10-03 | New England Deaconess Hospital Corporation | Dietary supplement utilizing ω-3/medium chain trigylceride mixtures |
| US4866040A (en) * | 1986-01-06 | 1989-09-12 | Alfred Stracher | Aminocarnitine directed pharmaceutical agents |
| US4742081A (en) * | 1986-01-06 | 1988-05-03 | Alfred Stracher | Carnitine coupled pharmaceutical agents |
| DE3620433A1 (de) | 1986-06-18 | 1987-12-23 | Boehringer Ingelheim Kg | Verwendung von 2-(n-2,6-dichlorphenyl-n-allyl-amino)-imidazolin-(2) als cytoprotektives mittel |
| DE68904874T2 (de) | 1988-10-31 | 1993-07-15 | Sandoz Nutrition Ltd | Organische verbindungen. |
| US5000975A (en) * | 1988-12-29 | 1991-03-19 | American Home Products Corporation | Randomized palm oil fat composition for infant formulas |
| CA2010511A1 (en) | 1989-03-01 | 1990-09-01 | Roberto L. Ceriani | Method of enhancing cancer therapy by administration of unsaturated fatty acids |
| US5457130A (en) * | 1989-03-20 | 1995-10-10 | Cancer Research Campaign Technology Limited | Eicosapentaenoic acid used to treat cachexia |
| GB8906369D0 (en) * | 1989-03-20 | 1989-05-04 | Tisdale Michael J | Eicosapentaenoic acid |
| US5157022A (en) | 1989-11-22 | 1992-10-20 | Adrian Barbul | Method for reducing blood cholesterol using arginine |
| US5087472A (en) * | 1990-01-30 | 1992-02-11 | Iowa State University Research Foundation, Inc. | Feed compositions for domestics animals containing hydroxymethylbutyrate |
| US5028440A (en) * | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| US4992470A (en) * | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
| US5167957A (en) * | 1990-09-06 | 1992-12-01 | Virginia Tech Intellectual Properties, Inc. | Compositions and methods for the treatment of dietary deficiencies |
| US5601860A (en) * | 1990-11-30 | 1997-02-11 | American Home Products Corporation | Corandomized fat compositions for infant formulas |
| KR100219771B1 (ko) | 1991-03-18 | 1999-10-01 | 이치로 키타사토 | 돼지용 사료 및 이를 사용하는 돼지 사육법 |
| US5085883A (en) | 1991-06-27 | 1992-02-04 | Abbott Laboratories | Blend of dietary fiber for nutritional products |
| US5171442A (en) * | 1991-10-18 | 1992-12-15 | Nakshbendi Ghassan F | Water purification apparatus |
| US5223285A (en) * | 1992-03-31 | 1993-06-29 | Abbott Laboratories | Nutritional product for pulmonary patients |
| WO1994006417A1 (en) * | 1992-09-16 | 1994-03-31 | Iowa State University Research Foundation, Inc. | Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol |
| US5447732A (en) | 1992-11-25 | 1995-09-05 | Ajinomoto Co., Inc. | High-absorption mineral-containing composition and foods |
| US5348979A (en) | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
| WO1994026855A1 (en) | 1993-05-13 | 1994-11-24 | Loders-Croklaan | Human milk fat replacers from interesterified blends of triglycerides |
| US6136858A (en) * | 1994-01-10 | 2000-10-24 | Abbott Laboratories | Infant formula and methods of improving infant stool patterns |
| US5780451A (en) * | 1994-04-01 | 1998-07-14 | Abbott Laboratories | Nutritional product for a person having ulcerative colitis |
| US5444054A (en) * | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
| US5952314A (en) * | 1994-04-01 | 1999-09-14 | Demichele; Stephen Joseph | Nutritional product for a person having ulcerative colitis |
| US5576287A (en) * | 1994-04-29 | 1996-11-19 | Wake Forest University | Method for treating acute renal disease and failure |
| US5726146A (en) * | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
| KR0140248B1 (ko) | 1995-03-23 | 1998-06-15 | 한상기 | 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법 |
| DE19528461A1 (de) | 1995-08-03 | 1997-02-06 | Braun Melsungen Ag | Präparat zur Ernährung |
| US5641531A (en) | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
| EP0866666B1 (en) | 1995-12-15 | 2000-07-05 | The Procter & Gamble Company | Beverages having stable flavor/cloud emulsions in the presence of polyphosphate-containing preservative systems and low levels of xanthan gum |
| EP1006806B1 (en) * | 1996-04-11 | 2006-09-13 | Loders Croklaan B.V. | Free flowing fat compositions |
| US6077828A (en) * | 1996-04-25 | 2000-06-20 | Abbott Laboratories | Method for the prevention and treatment of cachexia and anorexia |
| US5756469A (en) | 1996-07-26 | 1998-05-26 | Beale; Paxton K. | Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal |
| US7504376B2 (en) * | 1996-08-12 | 2009-03-17 | Natural Alternatives International | Methods and compositions for increasing the anaerobic working capacity in tissues |
| US6080788A (en) * | 1997-03-27 | 2000-06-27 | Sole; Michael J. | Composition for improvement of cellular nutrition and mitochondrial energetics |
| DE29707308U1 (de) | 1997-04-23 | 1997-06-26 | Kunz, Armin, 66450 Bexbach | Präparat zur Muskelerhaltung bzw. zur Förderung des Muskelaufbaus |
| US6660258B1 (en) * | 1997-05-09 | 2003-12-09 | Pharma Pacific Pty Ltd | Oromucosal cytokine compositions and uses thereof |
| US6103764A (en) * | 1997-11-07 | 2000-08-15 | Iowa State University Research Foundation, Inc. | Method for increasing the aerobic capacity of muscle |
| US6013665A (en) | 1997-12-16 | 2000-01-11 | Abbott Laboratories | Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides |
| US6194379B1 (en) | 1998-05-01 | 2001-02-27 | Abbott Laboratories | Elemental enteral formula |
| US6475539B1 (en) | 1998-05-07 | 2002-11-05 | Abbott Laboratories | Nutritionally complete low pH enteral formula |
| JP4175698B2 (ja) * | 1998-06-19 | 2008-11-05 | サントリー株式会社 | 新規なトリグリセリド及びそれを含む組成物 |
| US6031000A (en) * | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| ES2235499T3 (es) | 1998-07-30 | 2005-07-01 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena. |
| US5976550A (en) * | 1998-11-20 | 1999-11-02 | Engel; Peter H. | Dietary food supplement |
| US20010008641A1 (en) * | 1998-11-25 | 2001-07-19 | R. Douglas Krotzer | Nutritionally active composition for bodybuilding |
| JP3973786B2 (ja) | 1998-12-28 | 2007-09-12 | 松下電器産業株式会社 | スパッタリング方法及び装置 |
| US6294206B1 (en) * | 1999-04-09 | 2001-09-25 | Abbott Laboratories | Powdered human milk fortifier |
| US6291525B1 (en) * | 1999-09-08 | 2001-09-18 | Iowa State University Research Foundation, Inc. | Method for improving a human's perception of his emotional state |
| WO2001028356A2 (en) * | 1999-10-18 | 2001-04-26 | Muscletech Research And Development Inc. | Food supplement for increasing lean mass and strength |
| GB9929919D0 (en) | 1999-12-17 | 2000-02-09 | Hannah Research Inst The | Calcium phosphate nanoclusters and their applications |
| US6521591B1 (en) * | 2000-02-10 | 2003-02-18 | N.V. Nutricia | Pharmaceutical composition for muscular anabolism |
| US7250397B2 (en) * | 2000-02-23 | 2007-07-31 | Zealand Pharma A/S | Antiarrhythmic peptides |
| WO2001077271A2 (en) | 2000-04-06 | 2001-10-18 | Conlinco, Inc. | Conjugated linoleic acid compositions |
| JP4625156B2 (ja) * | 2000-04-10 | 2011-02-02 | イーエヌ大塚製薬株式会社 | 癌化学療法に伴う副作用軽減剤 |
| US6420342B1 (en) * | 2000-05-08 | 2002-07-16 | N.V. Nutricia | Nutritional preparation comprising ribose and medical use thereof |
| US20050106219A1 (en) * | 2000-05-30 | 2005-05-19 | Karlheinz Bortlik | Primary composition comprising a lipophilic bioactive compound |
| BR0112913A (pt) | 2000-08-03 | 2006-02-21 | Univ North Carolina State | aumento do desenvolvimento das espécies ovìparas por alimentação in ovo |
| DE50106272D1 (de) | 2000-08-29 | 2005-06-23 | Lonza Ag | Verfahren zur herstellung einer granulierbaren mischung und carnitin-magnesium-hydroxycitrat |
| US20030203070A1 (en) * | 2000-09-26 | 2003-10-30 | The Procter & Gamble Company | Compositions containing sorbitan monoesters |
| EP1198991B1 (en) * | 2000-10-20 | 2012-12-19 | Nutriz N.V: | Non-dairy products derived from rice |
| WO2002064714A1 (en) * | 2001-02-15 | 2002-08-22 | Asahi Denka Kogyo Kabushiki Kaisha | PRODUCTS CONTAINING $G(b)-GLUCAN |
| JP3735070B2 (ja) * | 2001-03-26 | 2006-01-11 | 花王株式会社 | 容器詰乳化飲料 |
| US6620427B2 (en) * | 2001-04-24 | 2003-09-16 | Abbott Laboratories | Method for improving bone mineralization |
| US20030021877A1 (en) * | 2001-06-13 | 2003-01-30 | Cain Frederick William | Micronised fat particles |
| DE10145818C1 (de) | 2001-09-17 | 2002-10-10 | Alfill Engineering Gmbh & Co K | Sterilisiervorrichtung mit H202-Verdampfer |
| GB2381451A (en) * | 2001-11-01 | 2003-05-07 | New Technology Res Ltd | Pharmaco-dietary preparation having nutrition-supplementing and nutrition-enhancing effect |
| JP2003137790A (ja) * | 2001-11-01 | 2003-05-14 | Mie Kariyou Kk | β−２，１（β２→β１）結合連鎖フラクトースオリゴマーを含有するフラクトオリゴ糖を有効成分とする医薬 |
| WO2003049832A1 (en) * | 2001-12-12 | 2003-06-19 | Martek Biosciences Boulder Corp. | Extraction and winterization of lipids from oilseed and microbial sources |
| US7168581B2 (en) * | 2001-12-21 | 2007-01-30 | Rexam Medical Packaging Inc. | Closure for a retort processed container having a peelable seal |
| DE10163676A1 (de) | 2001-12-21 | 2003-07-10 | Phenion Gmbh & Co Kg | Verwendung von Hyperforin oder Extrakten aus Johanniskraut gegen anaphylaktische Schockzustände oder Osteoporose |
| US20030165579A1 (en) | 2002-02-27 | 2003-09-04 | Chih-Hui Lin | Euphorbia antiquorum extract, a pharmaceutical composition containing the same and methods for treatment of cancers |
| ATE438621T1 (de) | 2002-04-23 | 2009-08-15 | Aventis Pharma Inc | 3-(substitutierte amino)-1h-indole-2- carbonsäureester und 3-(substitutierte amino)- benzoäbüthiophen-2-carbonsäureester verbindungen als inhibitoren der interleukin-4 genexpression |
| SE0201581D0 (sv) * | 2002-05-29 | 2002-05-29 | Scandinavian Biotechnology Res | New improved acyltransferase |
| WO2004002232A1 (en) * | 2002-06-28 | 2004-01-08 | Theuer Richard C | Fat compositions for infant formula and methods therefor |
| US20040048925A1 (en) * | 2002-09-09 | 2004-03-11 | Wiley David B. | Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives |
| US20040106678A1 (en) * | 2002-09-17 | 2004-06-03 | Dobbins Thomas A | Compositions for the parenteral administration of calcium and magnesium |
| WO2004035624A2 (en) * | 2002-10-14 | 2004-04-29 | Novo Nordisk A/S | Glucagon - like peptide - 2 variants |
| US7445807B2 (en) * | 2002-10-15 | 2008-11-04 | Western Holdings, Llc | Agglomerated granular protein-rich nutritional supplement |
| GB0301554D0 (en) | 2003-01-23 | 2003-02-26 | Molecularnature Ltd | Immunostimulatory compositions |
| US7332178B2 (en) * | 2003-04-25 | 2008-02-19 | Abbott Laboratories | Stable nutritional powder containing ascorbyl palmitate |
| FR2856596B1 (fr) | 2003-06-27 | 2007-04-27 | Bioprojet Soc Civ | Nouvelle association medicamenteuse psychiatrique et utilisation d'une antagoniste ou agoniste inverse du recepteur h3 de l'histamine pour preparer un medicament prevenant des effets indesirables de psychotropes. |
| JP2008500271A (ja) * | 2003-10-14 | 2008-01-10 | ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン | 免疫介在性疾患の治療および／または予防におけるアデニル酸シクラーゼ |
| IL158555A0 (en) * | 2003-10-22 | 2004-05-12 | Enzymotec Ltd | Human breast milk lipid mimetic as dietary supplement |
| ATE406884T1 (de) * | 2003-12-24 | 2008-09-15 | Nutricia Nv | Zusammensetzungen mit pantothensäure oder derivaten davon und ihre verwendung zur stimulierung des appetits |
| US7696241B2 (en) | 2004-03-04 | 2010-04-13 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US20050215640A1 (en) | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| US20050249650A1 (en) * | 2004-05-07 | 2005-11-10 | Fmc Technologies, Inc. | Immersion retort |
| EP1799052B2 (en) * | 2004-09-09 | 2020-01-08 | Société des Produits Nestlé S.A. | Methods for the manufacture of nutritional products having improved quality |
| WO2006031699A2 (en) * | 2004-09-10 | 2006-03-23 | Diversa Corporation | Compositions and methods for making and modifying oils |
| PL371081A1 (pl) | 2004-11-08 | 2006-05-15 | Sgp & Sons Ab | Preparat farmaceutyczny wpływający na procesy wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt oraz zastosowanie preparatu farmaceutycznego w procesie wzrostu i mineralizacji układu kostno-szkieletowego oraz chorób kości i chrząstki wieku dojrzałego u ludzi i zwierząt |
| US8067052B2 (en) * | 2005-02-25 | 2011-11-29 | Siddharth Shastri | Nutritional composition and a container for the convenient transport and storage of the nutritional composition |
| CA2537452C (en) * | 2005-03-09 | 2013-12-24 | Abbott Laboratories | Concentrated human milk fortifier liquid |
| RU2413430C2 (ru) * | 2005-04-27 | 2011-03-10 | Энзимотек Лтд. | Композиция жировой основы (варианты) и способ ее получения (варианты), композиция заменителя жира женского молока и способ ее получения (варианты), смесь для детского питания |
| MX2007013028A (es) * | 2005-06-06 | 2008-01-11 | Bristol Myers Squibb Co | Formulas infantiles con bajo contenido de fitato. |
| BRPI0615396A2 (pt) | 2005-08-26 | 2011-05-17 | Nestec Sa | composição nutricional para a prevenção ou tratamento de má-nutrição em um paciente obeso, bem como uso de uma fonte de proteìna, vitamina a, vitamina c, vitamina e, zinco e selênio para sua preparação |
| MY147363A (en) * | 2005-09-20 | 2012-11-30 | Nestec Sa | Water dispersible composition and method for preparing same |
| US20090182050A1 (en) | 2005-10-07 | 2009-07-16 | Ocean Nutrition Canada, Ltd. | Salts of Fatty Acids and Methods of Making and Using thereof |
| EP1973426A2 (en) * | 2005-11-03 | 2008-10-01 | Southwest Immunology Inc. | Compositions for preventing and reducing delayed onset muscle soreness |
| NZ568611A (en) | 2005-12-19 | 2011-11-25 | Abbott Lab | Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production |
| CA2637852A1 (en) * | 2006-01-31 | 2007-08-09 | Nestec S.A. | Nutritional composition for low birth weight infants |
| US20080119552A1 (en) * | 2006-11-17 | 2008-05-22 | Novus International Inc. | Matrix-embedded compositions having organic acids and fatty acids |
| US20080194407A1 (en) | 2007-02-14 | 2008-08-14 | Ashmead H Dewayne | High nitrogen containing chelate compositions suitable for plant delivery |
| US20090110674A1 (en) | 2007-10-24 | 2009-04-30 | Loizou Nicos C | Health supplement |
| US8029830B2 (en) * | 2008-04-18 | 2011-10-04 | Nuvocare Health Services Inc. | Composition and method for promoting internal health and external appearance |
| CA2723441A1 (en) | 2008-05-21 | 2009-11-26 | Stokely-Van Camp, Inc. | Milk-based recovery beverage |
| EP2381784B1 (en) | 2008-12-09 | 2018-07-11 | Metabolic Technologies, Inc. | Nutritional intervention for improving muscular function and strength |
| JP2009155336A (ja) | 2009-03-31 | 2009-07-16 | Tsujido Chemical Corp | 治療剤 |
| US20090312419A1 (en) | 2009-08-12 | 2009-12-17 | Kneller Bruce W | CREATINE -ßALANINATE: A NOVEL SALT FOR INCREASING ATHLETIC PERFORMANCE |
| PL217815B1 (pl) | 2009-12-14 | 2014-08-29 | Olimp Lab Spółka Z Ograniczoną Odpowiedzialnością | Napój izotoniczny z chelatami |
| CN101785566A (zh) | 2010-01-22 | 2010-07-28 | 北京康比特体育科技股份有限公司 | 一种含有hmb的运动饮料 |
| WO2011094557A1 (en) | 2010-01-29 | 2011-08-04 | Abbott Laboratories | Nutritional emulsions comprising calcium hmb |
| TWI526161B (zh) | 2010-06-10 | 2016-03-21 | 亞培公司 | 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液 |
| US10869843B2 (en) | 2010-11-23 | 2020-12-22 | Chemi Nutra | Method for increasing muscle mass and strength |
| SG191369A1 (en) | 2010-12-27 | 2013-08-30 | Abbott Lab | Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate |
| WO2012097061A1 (en) | 2011-01-13 | 2012-07-19 | Abbott Laboratories | Nutritional compositions and methods for improving skeletal muscle protein metabolism |
| TW201320908A (zh) | 2011-10-13 | 2013-06-01 | Abbott Lab | 包含β－丙胺酸之營養產品 |
| WO2013170189A1 (en) | 2012-05-11 | 2013-11-14 | Abbott Laboratories | Combination of beta - hydroxy - beta - methylbutyrate and beta - alanine for increasing muscle blood flow |
| WO2013188258A1 (en) | 2012-06-11 | 2013-12-19 | Abbott Laboratories | Use of hmb to improve health outcomes for hospitalized patients |
-
2004
- 2004-03-26 US US10/810,762 patent/US20050215640A1/en not_active Abandoned
- 2004-12-29 US US11/025,466 patent/US8217077B2/en not_active Expired - Fee Related
-
2005
- 2005-03-14 WO PCT/US2005/007951 patent/WO2005102301A2/en not_active Ceased
- 2005-03-14 KR KR1020067022383A patent/KR101253063B1/ko not_active Expired - Fee Related
- 2005-03-14 EP EP05732120A patent/EP1727534A2/en not_active Withdrawn
- 2005-03-14 MX MXPA06010922A patent/MXPA06010922A/es active IP Right Grant
- 2005-03-14 ES ES10186645.7T patent/ES2586402T3/es not_active Expired - Lifetime
- 2005-03-14 KR KR1020127033546A patent/KR20130010912A/ko not_active Ceased
- 2005-03-14 AU AU2005235133A patent/AU2005235133B2/en not_active Ceased
- 2005-03-14 EP EP11187274.3A patent/EP2444082B1/en not_active Expired - Lifetime
- 2005-03-14 BR BRPI0509017-2A patent/BRPI0509017A/pt active Search and Examination
- 2005-03-14 CA CA2807787A patent/CA2807787C/en not_active Expired - Lifetime
- 2005-03-14 JP JP2007504991A patent/JP5145033B2/ja not_active Expired - Fee Related
- 2005-03-14 CA CA2560042A patent/CA2560042C/en not_active Expired - Fee Related
- 2005-03-14 ES ES11187274T patent/ES2699161T3/es not_active Expired - Lifetime
- 2005-03-14 CN CNA2005800095960A patent/CN101212961A/zh active Pending
- 2005-03-14 EP EP10186645.7A patent/EP2301529B1/en not_active Expired - Lifetime
- 2005-03-25 TW TW094109357A patent/TWI369981B/zh not_active IP Right Cessation
-
2006
- 2006-09-12 IL IL178039A patent/IL178039A0/en unknown
- 2006-09-22 EC EC2006006873A patent/ECSP066873A/es unknown
-
2012
- 2012-01-11 US US13/347,985 patent/US20120177752A1/en not_active Abandoned
- 2012-01-11 US US13/347,956 patent/US8785495B2/en not_active Expired - Lifetime
- 2012-01-11 US US13/348,026 patent/US8609725B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/348,024 patent/US8785496B2/en not_active Expired - Lifetime
- 2012-01-11 US US13/348,035 patent/US8778994B2/en not_active Expired - Lifetime
- 2012-01-11 US US13/347,877 patent/US8778993B2/en not_active Expired - Fee Related
- 2012-01-11 US US13/347,978 patent/US20120189715A1/en not_active Abandoned
- 2012-06-21 JP JP2012139422A patent/JP5732437B2/ja not_active Expired - Fee Related
-
2015
- 2015-03-09 JP JP2015045519A patent/JP2015147773A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP066873A (es) | Compuestos hmb y usos parecidos | |
| AU2019203820B2 (en) | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution | |
| Serefko et al. | Magnesium in depression | |
| GB2596849A (en) | Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual | |
| Hu et al. | Pyruvate-enriched oral rehydration solution improved intestinal absorption of water and sodium during enteral resuscitation in burns | |
| Harada et al. | Withdrawal: Preventive Effect of Morinda citrifolia Fruit Juice on Neuronal Damage Induced by Focal Ischemia | |
| Paulis et al. | Peironimev-Plus® in the treatment of chronic inflammation of tunica albuginea (Peyronie's disease). results of a controlled study | |
| CA3235710A1 (en) | Topical compositions and methods for photodynamic therapy | |
| ES2250749T3 (es) | Uso de una composicion combinada que comprende propionil l-carnitina y otros farmacos para el tratamiento de la disfuncion erectil. | |
| US20040091506A1 (en) | Topical antifungal treatment | |
| GT200600263A (es) | Regimen de dosificacion para prasugrel | |
| JPWO2006080086A1 (ja) | 中枢神経系の疲労回復又は疲労予防のための組成物 | |
| US11116246B2 (en) | Compositions of coenzyme Q10 and methods of use | |
| RU2698396C1 (ru) | Фармацевтическая композиция для парентерального капельного введения | |
| Mychka et al. | Primary prophylaxis of cerebrovascular complications in patients with metabolic syndrome | |
| HU207800B (en) | Process for producing composition for improving condition and for treating different illnesses | |
| RU2695068C1 (ru) | Средство для лечения хронических облитерирующих заболеваний периферических сосудов на основе простагландина | |
| US20220409567A1 (en) | Adjuvant and complementary therapies for the treatment of cancer | |
| Kayıran et al. | Dermatological findings observed after renal transplantation in patients | |
| AU2018279043A1 (en) | Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution | |
| CN109803547A (zh) | 含有脱辅基水母素和维生素d的组合物及其使用方法 | |
| Marshall et al. | Role of Creatine Supplementation in Conditions Involving Mitochondrial Dysfunction: A Narrative Review. Nutrients 2022, 14, 529 | |
| RU2709502C1 (ru) | Фармацевтическая композиция для парентерального капельного введения | |
| Nagkrishna et al. | Evaluation of protective effect of vitamin-e on vincristine induced peripheral neuropathy in albino rats | |
| Nikolayevich et al. | Prevention of new-onset atrial fibrillation after direct myocardial revascularization surgery: randomized comparative study |